Posted by Michael Wonder on 15 Jun 2022
TGA approves Vyxeos
15 June 2022 - This marks the first TGA approval for Jazz Pharmaceuticals.
Vyxeos (cytosine arabinoside and daunorubicin hydrochloride) has been approved for the treatment of adults with newly diagnosed, therapy related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia related changes.
